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 2 
Abstract (max. 250 words) 20 
When bacteria evolve resistance against a particular antibiotic, they may 21 
simultaneously gain increased sensitivity against a second one. Such collateral 22 
sensitivity may be exploited to develop novel, sustainable antibiotic treatment strategies 23 
aimed at containing the current, dramatic spread of drug resistance. To date, the 24 
presence and molecular basis of collateral sensitivity has only been studied in few 25 
bacterial species and is unknown for opportunistic human pathogens such as 26 
Pseudomonas aeruginosa. In the present study, we assessed patterns of collateral 27 
effects by experimentally evolving 160 independent populations of P. aeruginosa to 28 
high levels of resistance against eight commonly used antibiotics. The bacteria evolved 29 
resistance rapidly and expressed both collateral sensitivity and cross-resistance. The 30 
pattern of such collateral effects differed to those previously reported for other bacterial 31 
species, suggesting inter-specific differences in the underlying evolutionary trade-offs. 32 
Intriguingly, we also identified contrasting patterns of collateral sensitivity and cross-33 
resistance among the replicate populations adapted to the same drug. Whole-genome 34 
sequencing of 81 independently evolved populations revealed distinct evolutionary 35 
paths of resistance to the selective drug, which determined whether bacteria became 36 
cross-resistant or collaterally sensitive towards others. Based on genomic and 37 
functional genetic analysis, we demonstrate that collateral sensitivity can result from 38 
resistance mutations in regulatory genes such as nalC or mexZ, which mediate 39 
aminoglycoside sensitivity in β-lactam-adapted populations, or the two-component 40 
regulatory system gene pmrB, which enhances penicillin sensitivity in gentamicin-41 
resistant populations. Our findings highlight substantial variation in the evolved 42 
collateral effects among replicates, which in turn determine their potential in antibiotic 43 
therapy. 44 
  45 
 3 
Introduction 46 
Bacteria have the potential to rapidly adapt to virtually any natural or laboratory 47 
environment (Kussell 2013). The long-term evolution experiment with Escherichia coli 48 
(LTEE) has shown that even in simple constant environments, bacteria can achieve 49 
comprehensive fitness increases of about 25% within the first 2,000 generations (Lenski 50 
et al. 1991). Although the LTEE populations show reduced adaptation rates at later time 51 
points (e.g., after 50,000 generations), they still continue to accumulate an almost 52 
constant number of new beneficial mutations (Barrick et al. 2009; Tenaillon et al. 53 
2016). Thus, bacteria can adapt rapidly to new challenges and subsequently continue to 54 
optimize their fitness. Such remarkable adaptive potential was also observed under 55 
more challenging conditions: Using evolution experiments with antibiotics, E. coli 56 
evolved high levels of drug resistance through the step-wise accumulation of multiple 57 
mutations when drug concentrations increased over time (Toprak et al. 2012) or across 58 
space (Baym, Lieberman, et al. 2016). Bacteria also readily adapted when they were 59 
challenged with two antibiotics simultaneously (Chait et al. 2007; Hegreness et al. 60 
2008; Michel et al. 2008; Pena-Miller et al. 2013), or sequentially (Kim et al. 2014; 61 
Fuentes-Hernandez et al. 2015; Roemhild et al. 2015).  62 
 63 
Rapid bacterial adaptation to new environments often involves evolutionary trade-offs 64 
in the form of reduced fitness under alternative growth conditions (Kussell 2013). In 65 
the case of antibiotic resistance evolution, two types of trade-offs (or costs) are 66 
commonly observed: (i) evolved resistance is costly in the absence of the drugs, thus 67 
generating growth deficiencies relative to the susceptible ancestor (Andersson and 68 
Hughes 2010; Melnyk et al. 2015), and (ii) resistance mutations may exacerbate 69 
susceptibility against others (i.e. collateral sensitivity (Szybalski and Bryson 1952; Pál 70 
et al. 2015); also referred to as hypersensitivity, or negative cross-resistance in previous 71 
publications). However, adaptive mutations do not always entail a cost but instead may 72 
increase resistance against other antibiotics (i.e., collateral resistance or cross-73 
resistance); thus favoring multi-drug resistance. 74 
 75 
The phenomenon of collateral sensitivity was first described in the 1950s in a study by 76 
Szybalski and Bryson, in which the authors tested if experimentally evolved resistant 77 
E. coli was less, equally or more sensitive to previously unmet drugs (Szybalski and 78 
Bryson 1952). Despite finding that cross-resistance was much more prevalent than 79 
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collateral sensitivity, the authors hypothesized that these rare cases could then be 80 
exploited by rationally using more than one drug during treatment of resistant clinical 81 
strains. The employment of drug pairs that produce reciprocal collateral sensitivity 82 
might trap bacteria in an evolutionary ‘double-bind’, thus improving treatment efficacy 83 
and decreasing the evolution of resistance. This idea was more recently tested by 84 
exposing bacteria to such drug pairs being deployed sequentially (Imamovic and 85 
Sommer 2013; Kim et al. 2014; Fuentes-Hernandez et al. 2015; Roemhild et al. 2015) 86 
or simultaneously (Munck et al. 2014; Evgrafov et al. 2015). Additionally, several other 87 
studies have further evaluated what factors could help to predict the changes in drug 88 
sensitivity in experimentally evolved resistant E. coli. These showed that the strength 89 
of selection and the chemogenomic profile similarity between antibiotics play 90 
significant roles in the evolution of resistance and hence influence the patterns of cross-91 
resistance and hypersensitivity (Lázár et al. 2013; Lázár et al. 2014; Oz et al. 2014). 92 
 93 
To fully determine the importance of such trade-offs during bacterial adaptation and 94 
also their therapeutic potential, the patterns of collateral resistance/sensitivity observed 95 
in E. coli need to be assessed in other, clinically relevant bacterial taxa, including those 96 
known to possess high adaptive capacity such as members of the genus Pseudomonas. 97 
This group of bacteria are able to colonize and thrive in a plethora of niches (Nikel et 98 
al. 2014), and act as prominent plant and human pathogens (Loper et al. 2012; 99 
Rodríguez-Rojas et al. 2012; Balasubramanian et al. 2013). For instance, the 100 
opportunistic human pathogen P. aeruginosa is commonly associated with hospital-101 
acquired infections, and it is a major cause of chronic lung disease, including the 102 
ultimately fatal infections in cystic fibrosis patients (Govan and Deretic 1996; Arruda 103 
et al. 1999; Kang et al. 2003; Folkesson et al. 2012). Its success as an opportunistic 104 
pathogen can be largely attributed to its vast array of virulence factors, including the 105 
production of alginate to form biofilms, its ability to survive oxidative stress, and the 106 
availability of various secretion systems (Hauser 2009; Ma et al. 2009; Burrows 2012; 107 
Jimenez et al. 2012; Korotkov et al. 2012). Moreover, it carries a large array of intrinsic 108 
antibiotic resistance mechanisms and an exceptional potential to acquire resistance, 109 
both de novo or horizontally transferred (Arruda et al. 1999; Carmeli et al. 1999; 110 
Hancock and Speert 2000; Poole 2001; Drenkard and Ausubel 2002; Livermore 2002; 111 
Overhage et al. 2008; Breidenstein et al. 2011). To date there is neither information on 112 
the evolution of drug sensitivity trade-offs in P. aeruginosa, nor on its genomic 113 
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underpinnings. To rectify this knowledge gap, we experimentally selected 160 highly 114 
resistant populations of P. aeruginosa PA14 (plus 20 control populations) and 115 
evaluated the possibility of evolutionary trade-offs in the form of fitness deficiencies in 116 
the absence of antibiotics and hypersensitivity to other drugs. We assessed the 117 
underlying molecular mechanisms of such trade-offs through whole-genome 118 
sequencing of 81 evolved resistant populations.  119 
 120 
Results and discussion 121 
Rapid evolution of antibiotic resistance 122 
We used experimental evolution to generate independent populations of P. aeruginosa 123 
PA14 with significantly increased resistance against eight different antibiotics. We 124 
challenged 20 isogenic populations against increasing concentrations of one out of eight 125 
different drugs (for abbreviations of all antibiotics see table 1), and included an 126 
evolutionary control grown in media only, resulting in a total of 180 independent 127 
populations. Experiments were initiated at half the concentration inhibiting >90% of 128 
growth (abbreviated IC90), as determined for the ancestral PA14. Populations were 129 
then serially transferred every 12 h for 24 days (48 transfers; approximately 58 130 
generations) until reaching around 40 times the IC90, or until less than half of the 131 
starting populations from a given antibiotic were still growing (fig. 1A). In the cases of 132 
DOR, IMI, and CAR, more than half of the populations went extinct at transfers 20, 28, 133 
and 40, respectively; we accordingly isolated 10 populations adapted to the 2x, 5x and 134 
17x environments for further analysis. In all other cases, we randomly chose 10 135 
surviving populations per antibiotic for subsequent characterization. Frozen 136 
populations adapted to GEN could not be recovered after thawing; we could only revive 137 
10 of those adapted to the 5x environment. Altogether we obtained 80 populations 138 
adapted to 8 different antibiotics and 10 additional ones adapted to media only.  139 
 140 
Table 1. List of antibiotics used during selection experiments. 141 
Functional target Class Drug Abbreviation 
DNA repair Quinolones Ciprofloxacin CIP 
Protein synthesis Aminoglycosides Gentamicin GEN 
Streptomycin STR 
Cell wall synthesis Penicillins Piperacillin + Tazobactam PIT 
Carbenicillin CAR 
 6 
Carbapenems Doripenem DOR 
Imipenem IMI 
Cephalosporins Cefsulodin CEF 
 142 
For the selected populations, we quantified the changes in resistance to the respective 143 
drug used during the evolution experiment (see Materials and Methods). P. aeruginosa 144 
could rapidly (within 58 generations or less) reach resistance levels of at least 32 times 145 
the IC90 of the ancestral PA14 for most antibiotics (fig. 1B-I). Interestingly, we 146 
observed substantial variation within particular drug treatments, suggesting different 147 
routes of adaptation to the antibiotic. Similar increases in drug resistance were found in 148 
a recent study with the related P. aeruginosa strain PAO1 (Cabot et al. 2016), 149 
highlighting the adaptive potential of this species. The same study also revealed in most 150 
cases an association of increased resistance with genomic changes in well-known 151 
resistance pathways. P. aeruginosa’s resistance thus appears to be achieved fast 152 
through diverse mechanisms. Several comparable E. coli evolution experiments 153 
resulted in similar levels of resistance, although variation between populations adapted 154 
to the same drug was less pronounced than observed here for P. aeruginosa (Imamovic 155 
and Sommer 2013; Lázár et al. 2013; Oz et al. 2014). 156 
 157 
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 158 
Fig. 1. Directional selection of highly resistant P. aeruginosa. (A) Illustration of the 159 
experimental design used for the selection of resistant populations. Twenty replicate 160 
populations for each of the eight included antibiotics (Table 1) and a control without 161 
antibiotic (a total of 180 populations) were serially transferred every 12h into fresh 162 
medium and, for the drug treatments, increasing concentrations of each drug. Selection 163 
was initiated at 0.5 times the concentration inhibiting >90% of growth (IC90) and 164 
concluded at ~40 times of the IC90. (B-I) Ten populations for each antibiotic were 165 
subsequently evaluated for their growth on different concentrations of the drug 166 
experienced during the experiment. Dose-response curves are shown in the left panels 167 
and IC90 fold changes in the right panels. The ten replicate populations are shown in 168 
different colors, while the black line represents the ancestral P. aeruginosa PA14.  169 
 8 
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Rapid resistance evolution entails a growth cost 171 
To evaluate whether the evolution of high drug resistance levels was generally 172 
associated with a fitness deficiency, we measured different growth parameters of all of 173 
the evolved populations, and the ancestral PA14 in a drug-free environment. We found 174 
that the control populations, which evolved without antibiotics, had significantly 175 
shorter lag phases and lower growth rates relative to the ancestor (supplementary fig. 176 
S1). These results suggest that adaptation to the medium alone can have strong effects 177 
on fitness. These effects could in turn influence antibiotic resistance. To evaluate this, 178 
we compared the sensitivity of the evolved control populations and the ancestor against 179 
each of the eight antibiotics. In general, we found no significant differences between 180 
the dose response curves of the controls and the ancestor (supplementary fig. S2). The 181 
only exceptions refer to cases at sub-inhibitory drug concentrations where the evolved 182 
populations showed higher growth than the ancestral PA14. More importantly, with 183 
only a single exception, none of the replicate populations showed a change in the IC90, 184 
thus indicating that the fitness alterations of the evolved controls do not translate into 185 
changes in drug sensitivity (supplementary fig. S2). 186 
 187 
As evolution in the absence of drugs affected growth characteristics, we specifically 188 
assessed the costs associated with the adaptation to antibiotics by relating our growth 189 
measures of the 80 resistant populations to those of the evolved controls. Resistant 190 
populations showed changes in at least one of the measured growth characteristics: lag 191 
time, growth rate, and maximum yield (fig. 2). In all cases, we observed a significantly 192 
longer time spent in lag phase, and in most cases (5 out of 8 drugs), a significant 193 
reduction of about 20-50% in maximum yield. Only populations adapted to PIT and 194 
GEN had significantly reduced growth rates. Overall, 90% of the resistant populations 195 
spent longer times in lag phase, 49% produced lower maximum yields, and 36% had 196 
lower growth rates (supplementary table S1). Interestingly, 60% of the resistant 197 
populations had a significant cost in at least two of the parameters, whereas only five 198 
of the populations showed no fitness costs at all.  199 
 200 
In most cases there was substantial variation among populations adapted to the same 201 
drug (fig. 2). This might have been the result of at least two paths: a direct outcome of 202 
costly adaptation resulting in varying lengths of lag phases depending on the favored 203 
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resistance mechanism, or, alternatively, an indirect consequence of our experimental 204 
design in which selection independently acted in favor of tolerance. In the latter case, 205 
an extended lag phase could have allowed P. aeruginosa to remain in the environment 206 
without immediately changing its initial resistance levels but instead increasing 207 
antibiotic tolerance. This could have ultimately resulted in varying levels of measured 208 
resistance among the various populations (Levin-Reisman et al. 2017). However, we 209 
found no significant correlation between the IC90 fold change and the lag time (or any 210 
of the growth parameters) for any of the antibiotics used (supplementary table S2 and 211 
supplementary fig. S3). This strongly suggests that the differences in resistance are not 212 
a result of selection for tolerance, but rather due to underlying differences in the 213 
resistance mechanisms that in turn have distinct effects on growth. This finding also 214 
means that the extent of the resistance increase does not linearly translate into a fitness 215 
cost, but most likely depends on the specific underlying mechanism. 216 
 217 
 218 
 219 
Fig. 2. Relative fitness in the absence of antibiotics. Shown, from top to bottom, is 220 
fitness relative to the average of the evolved control populations, calculated for growth 221 
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rate, lag time, and maximum yield for all populations adapted to one of the eight 222 
antibiotics (X-axis) after 24h of growth in antibiotic-free media. Colored points 223 
represent the replicate populations and the horizontal grey crossbars indicate the mean 224 
for each antibiotic. Black dashed lines highlight equality to the controls; values above 225 
indicate a fitness advantage whereas values below denote a cost. Plase note that for the 226 
lag phase, this is inverted: values larger than 1 indicate a longer time spent in lag phase 227 
and thus a fitness cost. Asterisks on top of each panel indicate significant difference 228 
from 1 (i.e., a significant change in fitness) using a Wilcoxon Rank test with probability 229 
adjustment based on the false discovery rate (FDR) to account for multiple testing. 230 
 231 
 232 
The extent to which growth costs are associated with antibiotic resistance evolution has 233 
been evaluated for a variety of combinations of bacteria and drugs, including P. 234 
aeruginosa (Kugelberg et al. 2005; Andersson and Hughes 2010; Melnyk et al. 2015). 235 
These studies demonstrated that mutations conferring high levels of resistance usually 236 
lead to larger fitness costs. Moreover, after adaptation to increasing drug 237 
concentrations, a higher number and more complex types of mutations (i.e., large 238 
deletions) coincide with larger defects in growth rate (Lázár et al. 2014). Considering 239 
such substantial resistance costs, it is surprising that resistant mutants persist both in 240 
clinical and experimental environments. Several factors were previously found to 241 
ameliorate or completely alleviate the effects of resistance mutations on growth. For 242 
instance, quinolone resistant P. aeruginosa showed a high prevalence of cost-free 243 
mutations as well as the emergence of compensatory mutations in genes that, 244 
unexpectedly, are not directly associated to the fitness defect (Kugelberg et al. 2005). 245 
In fact, some of our populations showed an increase in fitness in some or all of the 246 
growth parameters measured, emphasizing that the costs associated with some resistant 247 
mechanisms can be ameliorated rapidly (within 58 generations) or incur no costs at all. 248 
Furthermore, the role of epistatic effects, the genetic background in which mutations 249 
occur, and the environment also seem to play an important role in the magnitude of the 250 
cost (Melnyk et al. 2015). Therefore, there is a lack of predictability, constraining the 251 
potential clinical use of such information for a rational design of treatment strategies.  252 
 253 
Comprehensive collateral effects upon antibiotic resistance evolution 254 
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We then tested the evolved populations for the presence of collateral sensitivity or 255 
resistance against all other drugs. For this we challenged each population against 256 
various concentrations (in triplicate) of all the antibiotics and compared their growth to 257 
the ancestral PA14. To quantify the change in resistance or sensitivity we considered 258 
growth relative to the no-drug environment, which accounts for general fitness changes 259 
resulting from adaptation to the experimental environment. We then calculated the area 260 
under the curve (AUC) of the ancestral PA14 and subtracted it from that of each 261 
population (fig. 3A and B, for the IC90 fold changes see supplementary fig. S4). 262 
Finally, we counted how often adaptation to one antibiotic led to resistance against any 263 
other, hereby defined as direct adaptation, and also; how many times resistance to a 264 
given drug evolved after adaptation to another one, hereby defined as indirect 265 
adaptation (fig. 3C). The same process was repeated to calculate the number of cases 266 
of sensitivity by direct or indirect adaptation.  267 
 268 
 269 
 270 
 271 
Fig. 3. Evolution of collateral sensitivity and resistance. (A) Illustration of the 272 
quantification of evolved collateral resistance or sensitivity. Bacterial growth (relative 273 
to a no-drug environment) of all evolved populations and the ancestral P. aeruginosa 274 
PA14 is first measured across concentrations of the various antibiotics. The area under 275 
the curve of the ancestor is subsequently subtracted from that of each population; 276 
resulting negative values indicate sensitivity (bottom panel), whereas positive values 277 
denote resistance (top panel). (B) The collateral profiles of all experimentally evolved 278 
populations (rows refer to the drugs used during experimental evolution), challenged 279 
against all other antibiotics (as indicated by columns). The vertical bars within each 280 
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block represent the replicate population. The different shades of purple or green 281 
highlight the extent of sensitivity or resistance, respectively. (C) We counted the total 282 
number of cases, for which adaptation to a particular antibiotic (listed in the middle) 283 
led to collateral sensitivity or resistance (direct adaptation; left panel), and also the total 284 
number of cases, for which sensitivity or resistance towards the focal antibiotic was 285 
observed upon adaptation to any of the other drugs (indirect adaptation; right panel).  286 
 287 
Overall, we identified collateral effects in almost all population with evolved 288 
resistances, whereby cross-resistance is generally more common than collateral 289 
sensitivity (supplementary fig. S5 and fig. 3B and C; direct adaptation). Essentially 290 
identical results are obtained if IC90 fold change is used for the analysis rather than 291 
AUC differences (supplementary fig. S4). Five main conclusions can be drawn from 292 
our analysis. (i) Adaptation to a given antibiotic leads to collateral resistance to drugs 293 
of similar classes (see the aminoglycosides STR, and GEN, or the β-lactams CEF, PIT 294 
and CAR). (ii) Resistance to most drugs leads to collateral sensitivity against 295 
aminoglycosides, whereas resistance to aminoglycosides leads to collateral sensitivity 296 
almost exclusively to the penicillin-type β-lactams (PIT and CAR; fig. 3B and C; 297 
indirect adaptation). (iii) Adaptation to CIP or DOR leads to enhanced sensitivity 298 
against most other drugs, but interestingly this effect appears to be unidirectional: 299 
adaptation to other antibiotics rarely leads to sensitivity against these two drugs (fig. 300 
3C; indirect resistance). (iv) Collateral resistance against CEF, a 3rd generation 301 
cephalosporin with specific activity against P. aeruginosa, is found upon resistance 302 
evolution towards all other drugs, suggesting that resistance to some cephalosporins 303 
may be readily achieved indirectly, thus compromising its use as a second-line drug. 304 
(v) In several cases, substantial variation was observed among populations adapted to 305 
the same drug, suggesting that different resistance mechanisms may lead to contrasting 306 
patterns of collateral effects.  307 
 308 
The evolution of collateral resistance and sensitivity seems to be a widespread trade-309 
off in bacteria following drug resistance evolution. For example, in E. coli, collateral 310 
resistance towards drugs of the same class was repeatedly observed (Imamovic and 311 
Sommer 2013; Lázár et al. 2013; Lázár et al. 2014; Oz et al. 2014). These previous 312 
studies also revealed interesting exceptions. Some drugs, such as CIP, were often 313 
targets of indirect multi-drug resistance evolution, regardless of the similarity of the 314 
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drug used during experimental evolution. Also, the strength of cross-resistance was 315 
variable even among drugs with the same cellular targets. For instance, within the cell-316 
wall inhibitors, adaptation to penicillins seems to lead to cross-resistance more often 317 
than adaptation to carbapenems.  318 
 319 
It is noteworthy that the direction of collateral sensitivity differs in specific cases 320 
between P. aeruginosa and E. coli. In particular, resistance to the aminoglycosides 321 
often preceded a two-fold reduction in MIC against most other drugs in E. coli 322 
(Imamovic and Sommer 2013; Lázár et al. 2013). In contrast, adaptation to the same 323 
drugs in PA14 more often led to cross-resistance, while in some individual populations 324 
collateral sensitivity was observed almost exclusively towards the penicillins. 325 
Moreover, CIP-adapted E. coli strains usually exhibited cross-resistance to most other 326 
drugs (Imamovic and Sommer 2013; Lázár et al. 2014), while our experiments with P. 327 
aeruginosa produced hypersensitivity in such combinations. These findings highlight 328 
the presence of key differences between species in the evolved collateral effects 329 
following drug adaptation. Systematic evaluation of different pathogen-drug 330 
combinations is thus essential for a full appreciation of incidences and diversity of 331 
evolved collateral sensitivity (Imamovic and Sommer 2013; Lázár et al. 2014).  332 
 333 
Unexpectedly, our results further demonstrate the presence of substantial variation in 334 
collateral effects upon adaptation to one drug. In several cases, we even observed 335 
contrasting patterns of either collateral sensitivity or resistance. For example, CEF-336 
adapted populations exposed to GEN produced three cases of cross-resistance, five 337 
cases of collateral sensitivity, and two neutral effects (fig. 3A; fig. S4). Similar variation 338 
in collateral effects are also found for all other antibiotic treatments, with the exception 339 
of IMI, most likely due to low sample size (i.e., only 2 populations could be included 340 
in the analysis). Moreover, such divergence in collateral effects upon antibiotic 341 
resistance evolution has not yet been reported for other bacterial species. These findings 342 
strongly suggest that our replicate P. aeruginosa populations from a particular 343 
antibiotic treatment achieved resistance through different molecular mechanisms, 344 
which in turn had opposite effects on the interaction with a second antibiotic. 345 
 346 
Cross-resistance may result from the chemical similarity between drugs  347 
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Recent studies have followed Szybalski and Bryson’s hypothesis that the chemical 348 
relatedness between different drugs could explain the prevalence of cross-resistance, 349 
finding a partial correlation between them in E. coli (Lázár et al. 2014). However, the 350 
reported relationship was strongly biased by the aminoglycosides, since no cross-351 
resistance to such drugs was observed and these possess a chemical structure that is 352 
fundamentally different to that of the other drugs. In the case of P. aeruginosa, we often 353 
observed cross-resistance to the aminoglycosides, thus allowing us to further explore 354 
the range of relationships between drug similarities and the frequency of cross-355 
resistances. For such an analysis, we first inferred the chemical similarity among all 356 
antibiotics by calculating the Jaccard’s index obtained from the pairwise comparison of 357 
their chemical fingerprints (supplementary fig. S6). We then related these similarities 358 
to the frequencies of collateral resistances (FCR) for all drug pairs (see Materials and 359 
Methods, and Lázár et al. 2014). Our analysis revealed a significant correlation between 360 
these two parameters (fig. 4). Importantly, drugs targeting the same cellular process are 361 
not necessarily chemically similar (e.g., IMI and PIT or DOR and CAR) and in these 362 
cases we do not find high levels of cross-resistance. Altogether, chemical similarity 363 
appears in most cases to be a key determinant of the probability of cross-resistance.  364 
 365 
 366 
 367 
Fig. 4. Chemical similarity correlates with frequency of collateral resistance. Pairwise 368 
Jaccard’s similarity indexes where calculated based on the chemical fingerprints of 369 
each antibiotic. The frequency of collateral resistance (FCR) was then determined as 370 
, where RAB is the number of populations resistant to drug 371 
A with cross-resistance to drug B (and vice versa for RBA), and LAB is the total number 372 
of populations adapted to A and B. A significant correlation was then found between 373 
the chemical similarity and the FCR (Spearman’s rank correlation). Each point 374 
FCR= RA®B +RB®A( ) / LAB
 15 
corresponds to a chemical comparison between any two given drugs. Labels are shown 375 
for some, but not all, of these pairwise comparisons.  376 
 377 
Distinct mutations underlie the evolution of high antibiotic resistance 378 
To better understand the genetic mechanisms selected during the evolution of high 379 
antibiotic resistance, we obtained whole genome sequences for 81 evolved populations: 380 
71 antibiotic adapted populations and 10 controls. We characterized genomic variations 381 
using a previously established analysis pipeline (see Materials and Methods; Jansen et 382 
al. 2015). An important step of the pipeline is to remove substitutions which occurred 383 
in the control populations, as these may result from adaptation to general experimental 384 
conditions and could thus obscure the signals relevant for adaptation to the antibiotics 385 
(see supplementary table S4 for a list of mutations found in the evolved control 386 
populations). We further annotated the genes with mutations in coding regions using 387 
DAVID, the Pseudomonas Database (available online at: http://pseudomonas.com), 388 
and published information to group them by function and their likely involvement in 389 
antibiotic resistance. In general, we observed an average of 10.5 genes affected per 390 
antibiotic environment (fig. 5A), but with different degrees of mutational diversity 391 
(supplementary fig. S7). Most mutations were non-silent and may thus have contributed 392 
to adaptation (fig. 5B and C): 89% of the mutations were observed in coding regions 393 
(Intergenic vs. all other mutations, χ2 test, χ2 = 50.94, df = 1, P < 0.0001); 83% of the 394 
variants found in coding regions (e.g., different types of non-synonymous, 395 
insertions/deletions [indels], or frameshift mutations) led to partial or complete loss of 396 
function (Intergenic and Synonymous SNPs vs. all other type of variants, χ2 test, χ2 = 397 
39.15, df = 1, P < 0.0001), and more than half of the variants observed were fixed at 398 
levels above 40% (Number of variants <40% fixed vs. variants ≥40% fixed, χ2 test, χ2 399 
= 50.94, df = 1, P = 0.003).  400 
 401 
For subsequent analysis we focused on genes having mutations in their coding regions 402 
only (fig. 5D). Interestingly, the only two surviving populations adapted to IMI showed 403 
mutations in mutL, a gene coding for a DNA repair enzyme generally associated with 404 
hypermutator phenotypes (Oliver et al. 2002; Montanari et al. 2007; Ciofu et al. 2010); 405 
these populations accumulated as many mutations in half the number of generations as 406 
the others during the entire experiment (supplementary table S5). The various DOR 407 
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adapted populations produced a unique SNP in a single gene, oprD: a membrane protein 408 
(fig. 5D). The populations adapted to all other antibiotics showed a larger number of 409 
genomic changes across a variety of genes (fig. 5D).  410 
 411 
 412 
Fig. 5. Genomics of adaptation. Distribution of the number of genes with substitutions 413 
per (A) antibiotic used in the evolution experiment, (B) type of mutational change, and 414 
(C) average frequency class within the replicate populations. (D) Functional effect of 415 
mutations found in coding regions of the listed genes (vertical axis, left side) across 416 
evolution experiments with different antibiotics (horizontal axis). Functional 417 
information (right side) is inferred from a combined analysis using DAVID, the 418 
Pseudomonas database and publications. Different shades of red indicate the percentage 419 
of affected populations per evolution experiment with a particular antibiotic.  420 
 421 
The functional annotation revealed changes in three main functions across evolved 422 
populations (fig. 5D): The first group of affected genes is related to direct targets of the 423 
β-lactam antibiotics and was primarily identified in populations adapted to CEF, CAR 424 
and PIT. This group included genes associated with peptidoglycan synthesis 425 
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(supplementary table S4): the penicillin-binding protein 3 (PBP3) ftsI, and also the 426 
UDP-N-acetylmuramate: L-alanyl-gamma-D-glutamyl-meso-diaminopimelate ligase 427 
mpI. Non-silent mutations in these genes were previously demonstrated to increase 428 
resistance against β-lactams, either by limiting the interaction between antibiotics and 429 
the products of these genes, or by indirectly inducing SOS responses or enhanced efflux 430 
(Miller et al. 2004; Tsutsumi et al. 2013). 431 
 432 
The second group of genes is related to 7 different two-component regulatory systems 433 
(fig. 5D). This group was generally affected in response to adaptation to β-lactam and 434 
aminoglycoside antibiotics; whereby variation in mutated systems seem to depend on 435 
the antibiotic class. Two-component systems are essential for bacteria to recognize 436 
different environmental stimuli and coordinate a fine-tuned response via a complex 437 
phosphorylation signal transduction system (Hoch 2000; Robinson et al. 2000; Ramos 438 
et al. 2005). P. aeruginosa in particular possesses a large number of such regulatory 439 
systems, which it uses to control cellular division, development, stress responses, and 440 
pathogenicity (Rodrigue et al. 2000).  441 
 442 
The third main group of mutated genes was found in β-lactam and aminoglycoside 443 
adapted populations, and included different efflux regulatory systems (fig. 5D). These 444 
genes modulate the activity of distinct efflux pumps which can lead to single or multi-445 
drug resistance (Hancock and Speert 2000; Li et al. 2000; Poole 2001; Piddock 2006). 446 
Importantly, two of them (mexZ and nalC) are closely related to those regulating the tet 447 
efflux pumps (TetR-like repressors), which were previously demonstrated to contribute 448 
to collateral sensitivity against aminoglycosides in tetracycline resistant E. coli 449 
(reviewed in Baym, Stone, et al. 2016). These genes were further proposed as a pivotal 450 
group to be exploited in sequential treatment strategies (Baym, Stone, et al. 2016).  451 
 452 
We additionally identified changes in several other known or at least suggested 453 
antibiotic resistance genes (fig. 5D), including the membrane protein main component 454 
oprD, the DNA gyrase subunits gyrA and gyrB, as well as other genes involved in 455 
cellular processes such as cell division and motility (Macfarlane et al. 2000; Drenkard 456 
and Ausubel 2002; Livermore 2002; Amin et al. 2005). Our analysis further revealed 457 
changes in genes with currently unknown function and/or no previous implication in 458 
antibiotic resistance, and/or mutations in non-coding regions, which may still influence 459 
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resistance if regulatory regions are affected (e.g., possibly relevant for DOR-adapted 460 
populations). Some of these changes occurred at lower frequency within the replicate 461 
populations, but their exact contribution to the observed evolutionary pattern is 462 
uncertain and may be interesting to address in future studies. Furthermore, among the 463 
PIT-adapted populations we also found substantial variation in the sets of mutated 464 
genes, even though they almost all consistently affected the same two functional 465 
categories: peptidoglycan synthesis and efflux regulatory systems. This variation could 466 
explain the different levels of resistance observed for these populations, whereby 467 
different groups of mutated genes lead to higher or lower levels of resistance. 468 
 469 
Specific resistance mechanism associate with high growth costs 470 
The accumulation of multiple mutations during adaptation to antibiotics could translate 471 
into stronger reductions in fitness under drug-free conditions. In fact, in a similar study 472 
with E. coli, populations accumulating a large number of mutations or deletions had 473 
also very low fitness in drug-free environments (Lázár et al. 2014). Similarly, in P. 474 
aeruginosa we found that the populations with the strongest decrease in growth rate 475 
have a significantly larger number of mutations in their genomes (supplementary fig. 476 
S8A). However, none of the other measured fitness parameters correlated with the 477 
number of mutations, suggesting that this alone is not enough to explain the observed 478 
variation in fitness. Moreover, when we looked for overrepresented genes in 479 
populations with the most extreme growth costs, we observed some functions to be 480 
more prevalent than others (supplementary fig. S8B-D). In particular, genes involved 481 
in peptidoglycan synthesis (mpl, dacC or ftsI), regulation of efflux (nalC) or part of 482 
two-component regulatory systems (pmrB) were more frequently found in populations 483 
with lower relative fitness across the measured growth parameters. Interestingly, 484 
multiple genes affecting these cellular processes were found within the same 485 
populations having strong fitness reductions (nalC together with mpl and dacC were 486 
often found in PIT resistant populations). Altogether, the costs of adaptation seem to 487 
be dependent on both the number of mutations accumulated and the specific mutated 488 
resistance mechanism.  489 
 490 
Parallel patterns of collateral resistance across treatments is not linked to similar 491 
mutational profiles 492 
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Next, we assessed whether parallel mutational changes could explain the observed 493 
patterns of collateral resistance across different treatments in P. aeruginosa (Fig. 3B). 494 
In contrast to the findings for E. coli (Lázár et al. 2014), we found comparatively little 495 
mutational overlap between the populations from different antibiotic treatments 496 
(supplementary fig. S9A). Interestingly, in the few cases where similar mutational 497 
profiles were observed among populations resistant to different drugs, the two 498 
compared antibiotics appear to be chemically related, and the populations showed 499 
cross-resistance (supplementary fig. S9B and C). However, these correlations were not 500 
statistically significant, because our data set also included several populations with high 501 
cross-resistance against chemically similar drugs, but with completely distinct 502 
mutational profiles (supplementary fig. S9B and C). Therefore, it seems that the parallel 503 
patterns of cross-resistance across treatments are based on different sets of mutations.  504 
 505 
This is also true for populations from different treatments that adapted to drugs of the 506 
same class. For instance, the populations that adapted to the two aminoglycosides 507 
showed high levels of cross-resistance among them, but adaptation to GEN was more 508 
often accompanied by mutations in the two-component regulatory gene pmrB, while 509 
those adapted to STR predominantly showed mutations in genes involved in cellular 510 
division (i.e., gidA or gidB), or in efflux regulation (i.e., mexZ; fig. 5D and 511 
supplementary table S5).  512 
 513 
Contrasting collateral effects have unique genomic profiles 514 
We identified substantial variation in the incidence of collateral sensitivity and cross-515 
resistance within particular evolution experiments. For instance, five of the CEF 516 
adapted populations showed collateral sensitivity against GEN and STR, whereas the 517 
rest suffered cross-resistance or neutral effects against the same drugs (fig. 3B). 518 
Similarly, three of the GEN adapted populations displayed collateral sensitivity against 519 
CAR and PIT, while the others were resistant (fig. 3B). Such variation could be the 520 
result of distinct resistance mechanisms selected during adaptation to each drug, which 521 
in turn led to contrasting sensitivities against other antibiotics. To explore this 522 
possibility, we focused on four exemplary cases, for each of which we repeatedly found 523 
contrasting variation in collateral effects to other antibiotics. These included the 524 
populations adapted to the two aminoglycosides (GEN, STR), which both showed such 525 
variation towards PIT and CAR (Fig. 3B). We also considered the reverse two cases, 526 
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for which populations that had adapted to either PIT or CAR produced contrasting 527 
collateral patterns towards GEN and STR (Fig. 3B). For these four cases, we used 528 
hierarchical cluster analysis (based on Ward’s criterion method and bootstrapping to 529 
assess cluster stability (Murtagh and Legendre 2014)) to relate populations with varying 530 
collateral effects to corresponding genomic variation. In particular, we first assessed 531 
whether populations adapted to a given drug would cluster together based on their 532 
sensitivity against the two other antibiotics (fig. 6A, 6C, 6E, and 6G). Then, we asked 533 
whether the same populations would also cluster together based on their sets of mutated 534 
genes (fig. 6B, 6D, 6F, and 6H).  535 
 536 
 537 
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Fig. 6. Genomic determinants of collateral sensitivity. We employed a hierarchical 538 
clustering analysis using the Ward’s criterion method and bootstrapping to identify the 539 
genomic determinants of variation in collateral profiles in four treatments. In two of 540 
these treatments, replicate populations that had adapted to either GEN (A,B) or STR 541 
(C,D) produced variation in collateral profile to PIT and CAR. In the other two 542 
treatments, replicate populations that had adapted to either PIT (E,F) or CAR (G,H) 543 
showed such variation towards GEN and STR. We first evaluated the clustering of 544 
populations adapted to GEN (A), STR (C), PIT (E) and CAR (G) based on the strength 545 
of collateral effects to the other two drugs (Fig. 3B), highlighting clusters of those with 546 
collateral sensitivity (lines in different shades of purple, see legend to the right) versus 547 
those with collateral resistance (lines in different shades of grey). The circled numbers 548 
always indicate the same replicate populations from a particular treatment across the 549 
related panels. Populations clustering together based on their collateral effects also 550 
often clustered together based on their genomic profile (B, D, F, H). The mutated genes 551 
present in the various clusters are given to the right of the dendrograms, followed by 552 
letters for their functional annotation in brackets (see legend to the right for the 553 
annotation categories). If a specific cluster mainly included populations associated with 554 
collateral sensitivity, then the gene names are given in purple. In cases, where clusters 555 
mainly included populations associated with collateral resistance, the gene name is 556 
given in green. 557 
 558 
We identified clusters that consistently link the contrasting patterns of collateral 559 
sensitivity to particular genomic variations. Intriguingly, the two-component regulatory 560 
system and TetR-like repressors appear to play a pivotal role in determining these 561 
patterns. For the GEN-adapted populations, sensitivity to PIT and CAR was associated 562 
with mutations in pmrB (fig. 6A and 6B), a sensor kinase implicated in resistance 563 
against cationic antimicrobial peptides, polymyxins, and aminoglycosides in 564 
Salmonella and P. aeruginosa (McPhee et al. 2003). Aminoglycoside resistance 565 
mediated by pmrB is hierarchically controlled by two regulatory systems (PhoP-PhoQ 566 
and PmrB-PmrA) that ultimately remodel lipid A in the outer membrane resulting in a 567 
reduction of the membrane’s negative charge. Such alterations were shown to enhance 568 
sensitivity to β-lactams in aminoglycoside resistant E. coli (Lázár et al. 2013; Baym, 569 
Stone, et al. 2016). Altogether, this suggests that pmrB could be the main driver of β-570 
lactam sensitivity in GEN resistant populations.  571 
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 572 
Collateral sensitivity against penicillins in STR-adapted populations is linked to 573 
mutations in the gene mexZ (fig. 6C and D), a TetR-like repressor modulating the 574 
expression of the MexXY-OprM efflux system (Aires et al. 1999). This gene was found 575 
to mediate aminoglycoside resistance in P. aeruginosa PAO1 and clinical isolates from 576 
cystic fibrosis patients by increasing cellular drug efflux, trough an up-regulation of the 577 
mexXY genes (Westbrock-Wadman et al. 1999). Interestingly, in P. aeruginosa, 578 
extrusion of the aminoglycosides appears to be exclusively mediated by MexXY-579 
OprM, which, when overexpressed, is also able to extrude most penicillins (except for 580 
carbenicillin and sulbenicillin), some cephalosporins, and meropenem (Masuda et al. 581 
2000). However, to the best of our knowledge, its possible role in mediating collateral 582 
sensitivity against penicillins has not been reported before. In addition, the expression 583 
of collateral sensitivity could be further influenced by other mutations. For instance, a 584 
mutation in motB, a gene required for flagellar motility in P. aeruginosa (Doyle et al. 585 
2004), is present in addition to mutated mexZ in population 10, which shows collateral 586 
sensitivity to CAR but not PIT (fig. 6C and 6D).  587 
 588 
In the case of the penicillin-adapted populations, collateral sensitivity against 589 
aminoglycosides appears to be associated – among others – with mutations in the gene 590 
nalC, an efflux regulator of the MexAB-OprM system known to confer intermediate to 591 
high levels of resistance to multiple drugs (Cao et al. 2004). Populations adapted to 592 
CAR and PIT with mutations in this gene consistently showed a more sensitive 593 
phenotype against both aminoglycosides (fig. 6E-H). Interestingly, tet efflux regulators, 594 
which are related in their function to nalC, were previously shown to mediate collateral 595 
sensitivity against aminoglycosides in tetracycline resistant E. coli (reviewed in Baym, 596 
Stone, et al. 2016), thus suggesting a pivotal role of this type of resistance mechanism 597 
in determining antibiotic susceptibility trade-offs. 598 
 599 
It is noteworthy that the exact distribution of the variation in sensitivity against 600 
aminoglycosides in CAR-adapted populations is not well captured by our approach. All 601 
the identified clusters show genomic changes that affect the same three functions, yet 602 
the exact mutations and their frequencies within the populations differ (fig. 6G and H, 603 
supplementary fig. S10 and supplementary table S5). The observed phenotypic 604 
variation may then be caused by only some of the variable genes, by specific mutations 605 
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only, by the combination of specific allelic variants, or by the frequency difference of 606 
certain mutations. Therefore, the observed collateral effects are likely influenced by 607 
additional factors, which could not be identified directly by the cluster analysis. 608 
 609 
Mutations in nalC, mexZ, and pmrB can cause collateral sensitivity 610 
Different regulatory systems were generally associated with collateral sensitivities in 611 
the evaluated populations. To further evaluate such a role, we assessed antibiotic 612 
sensitivity in genetically modified ancestral PA14, in which we re-introduced a 613 
selection of four of the identified mutational changes (Materials and methods), namely 614 
the inferred ~500 bp deletion in nalC, a SNP in mexZ leading to an early stop codon 615 
(Q95stop), and two non-synonymous mutations in pmrB causing a P254L and a V136E 616 
amino acid substitution. In all cases, the constructed mutants showed almost the exact 617 
same response as the evolved populations against at least two of the considered 618 
antibiotics (fig. 7 and supplementary table S6). In particular, the SNPs introduced in 619 
pmrB and mexZ, originally observed in the GEN- and STR-adapted populations, caused 620 
high resistance to these aminoglycosides, and led to significantly increased sensitivity 621 
to the penicillins PIT and CAR (fig. 7; supplementary table S6). Similarly, the 622 
introduced deletion in nalC, originally observed in CAR-adapted populations, caused 623 
resistance to the tested penicillins while significantly increasing sensitivity to both GEN 624 
and STR (fig. 7; supplementary table S6). Thus, two-component regulatory systems 625 
and efflux regulators can be responsible for the observed collateral sensitivity in P. 626 
aeruginosa.  627 
 628 
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 629 
Fig. 7. Functional analysis of different regulatory genes. We focused on four specific 630 
mutations identified in the evolved populations to associate with collateral sensitivity 631 
and introduced these into the ancestral PA14 strain. The resulting mutants were then 632 
tested against various concentrations of CAR, PIT, GEN and CAR (from left to right). 633 
In all cases, the ancestral PA14 (always in black) and the adapted population (always 634 
in darker colors), from which the particular mutation was extracted, were tested 635 
simultaneously with the corresponding constructed mutants. Points and error bars show 636 
the mean OD ± SD of 5 technical replicates per antibiotic concentration. For each set 637 
of bacterial populations challenged against a particular drug we performed a GLM 638 
followed by Tukey’s honest significant difference (HSD) test. For a summary of the 639 
statistical results see supplementary table S5. 640 
 641 
The tested genes nalC, mexZ, and pmrB are involved in the regulation of efflux pumps 642 
or alteration of the outer membrane, and can thus influence antibiotic resistance 643 
(Westbrock-Wadman et al. 1999; McPhee et al. 2003; Cao et al. 2004; Daigle et al. 644 
2007; Lázár et al. 2013; Baym, Stone, et al. 2016). To the best of our knowledge, the 645 
results of our functional genetic analysis demonstrated for the first time in P. 646 
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aeruginosa that such genes can also differentially lead to collateral sensitivity against 647 
aminoglycosides (nalC) and penicillins (mexZ and pmrB). Importantly, two distinct 648 
aminoglycoside resistance mechanisms independently led to penicillin 649 
hypersensitivity: a loss of function (LOF) mutation in mexZ, and two different non-650 
synonymous mutations in the two-component regulatory system gene pmrB. 651 
Intriguingly, contrasting collateral effects emerged from alterations in functionally 652 
related genes: both mexZ and nalC are from the TetR-family of repressors, and LOF 653 
mutations in each of them led to completely opposite susceptibilities against penicillins 654 
and aminoglycosides. Such contrasting results could be due to an impairment of one of 655 
the efflux pumps upon up-regulation of the other, a phenomenon previously seen in 656 
other efflux systems such as MexCD and MexAB, or MexEF and MexAB (Gotoh et al. 657 
1998; Maseda et al. 2000; Jeannot et al. 2008), but not between MexXY and MexAB. 658 
 659 
Conclusions 660 
 661 
We here demonstrated that P. aeruginosa adapts rapidly to high-level antibiotic stress 662 
and that such adaptation may influence resistance against other antibiotics. Cross-663 
resistance correlates well with chemical similarity of the antibiotics, in agreement with 664 
previous work. Collateral sensitivity was identified in several cases, yet different in 665 
direction to those cases previously reported for other bacteria, such as E. coli. 666 
Surprisingly, adaptation to a particular antibiotic produced both cross-resistance and 667 
collateral sensitivity across the replicate populations. Our genomic analysis suggests 668 
that alternative mechanisms were favored during resistance evolution, which then 669 
resulted in these contrasting cross-resistance patterns. Intriguingly, regulatory systems 670 
appear to play a key role in mediating the observed collateral effects. Functional genetic 671 
analysis revealed that four of the identified mutations in three regulatory genes (nalC, 672 
mexZ, and pmrB) can indeed cause collateral sensitivities in P. aeruginosa. Overall, we 673 
expect our results to help the development of novel antibiotic therapy that exploits 674 
fitness trade-offs during drug resistance evolution. 675 
 676 
  677 
 26 
Materials and methods 678 
Bacteria and media 679 
All experiments were conducted with Pseudomonas aeruginosa PA14. Cells were 680 
grown at 37°C in sterile M9 minimal medium supplemented with 0.2% glucose and 681 
0.1% casamino acids. All antibiotics were prepared according to manufacturer’s 682 
instructions (Table 1). All experiments were carried out in 96-well plates shaken and 683 
incubated at 37°C for 12h and treatments being randomized across each plate. After 684 
12h of growth, optical density (OD) measurements were taken in BioTek plate readers. 685 
Randomization schemes of plates for each experiment were different from each other.  686 
 687 
Selection of highly resistant mutants 688 
We challenged 20 isogenic populations of PA14 against increasing concentrations of 689 
each of the studied antibiotics (160 populations in total; Fig. 1A). As a control for the 690 
adaptation to growth in medium without antibiotics we also included 20 populations 691 
growing in M9 only, resulting in a total of 180 populations. Experiments were initiated 692 
with half the antibiotic concentration that causes growth inhibition of at least 90% 693 
(IC90) for each drug in a final volume of 100µl per well. Every 12h 50% volume was 694 
transferred into a freshly prepared plate. Every fourth transfer (4 generations), OD was 695 
measured and the antibiotic concentration was increased 1.5 times. Experiments were 696 
concluded when reaching ~40 times the IC90 (48 transfers) or when 10 or less of the 697 
20 populations had reached extinction. Whenever the antibiotic concentration was 698 
increased, the preceding plates were frozen at -80°C in 1:4 (v/v) of 86% glycerol. 699 
 700 
Fitness measurements 701 
All evolved populations were grown overnight (ON) at 37˚C and 180rpm in M9 media 702 
with the corresponding antibiotic they were adapted to. Cultures were then centrifuged, 703 
washed with fresh M9 media and diluted in 100µl of M9 without any drug to a starting 704 
OD of 0.08 (~105 CFU/mL). For each population, 4 technical replicates were 705 
considered, and then incubated inside a plate reader at 37˚C for 24h. Within the plate 706 
reader, OD measurements were taken at regular intervals of 15 min, for a total of 96 707 
measurements per population and replicate. The collected growth data was then 708 
analyzed using the R package ‘grofit’ to obtain three growth parameters: growth rate, 709 
length of lag time, and maximum yield. We standardized the fitness of each population 710 
relative to the mean of the evolved controls (adapted to M9 media only).   711 
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 712 
Collateral sensitivity and resistance assays 713 
We measured collateral effects for the experimentally evolved populations with high 714 
levels of resistance. We tested these populations and also the ancestral PA14 against 10 715 
different concentrations of a given antibiotic in randomized order (each concentration 716 
was replicated 3 times; total of 21120 concentration and population combinations). To 717 
quantify the change in resistance or sensitivity we first considered growth relative to 718 
the no-drug environment in order to account for differences in fitness defects among 719 
populations originated after adaptation. We then calculated the area under the curve 720 
using a spline approximation of the ancestral PA14 and subtracted the one obtained for 721 
each population. Positive values reflect a higher cumulative growth at increasing 722 
concentrations in the population compared to the ancestor, thus indicating cross-723 
resistance; conversely, negative values represent collateral sensitivity. To derive 724 
significant sensitivity or resistance, we performed a Wilcox rank test for all populations 725 
adapted to a given environment when challenged against a given antibiotic, comparing 726 
significant differences from 0. P-values were adjusted for multiple testing using the 727 
false discovery rate, FDR (supplementary fig. S5). We subsequently asked how many 728 
cases of direct or indirect adaptation had occurred for each antibiotic. Direct adaptation 729 
considers how often adaptation to a given drug leads to resistance (or sensitivity) 730 
against other drugs, whilst indirect adaptation reflects how often adaptation to other 731 
drugs lead to resistance (or sensitivity) against a particular antibiotic. For example, we 732 
asked how many cases of resistance against all other drugs were observed upon 733 
adaptation to CIP (direct adaptation); as well as how many cases of resistance against 734 
CIP were found upon adaptation to any other drug (indirect adaptation).  735 
 736 
Chemical similarity 737 
We inferred chemical relatedness as previously described by using the Jaccard’s 738 
similarity index contrasting the chemical fingerprints of all antimicrobial compounds 739 
used here (Lázár et al. 2014). We then correlated these pairwise comparisons to the 740 
frequency of cross-resistance calculated by: 741 
 742 
, 743 
 744 
FCR= RA®B +RB®A( ) / LAB
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where RAB is the number of populations resistant to drug A with cross-resistance to 745 
drug B, RBA is the number of populations resistant to drug B with cross-resistance to 746 
A, and LAB is the total number of populations adapted to A and B. 747 
 748 
 749 
DNA extraction  750 
To identify the genetic changes leading to high-level resistance evolution, we 751 
sequenced full genomes for whole populations of the ancestral P. aeruginosa PA14, 10 752 
evolved controls and 71 populations adapted to different drugs. Frozen material from 753 
all populations was thawed, and 10µl of each were transferred into 15 ml of M9 minimal 754 
medium with the corresponding antibiotic. All populations were shaken and incubated 755 
at 37˚C ON. DNA was extracted using the DNeasy Blood & Tissue Kit (Qiagen, 756 
Hilden, Germany) following manufacturer’s recommendations for Gram-negative 757 
bacteria. Eighty-one populations in total were sequenced at the Institute for Clinical 758 
Microbiology, Kiel University Hospital, using the Illumina HiSeq paired-end 759 
technology (Bentley et al. 2008) with an insert size of 150bp and 300x coverage. 760 
 761 
Genomic analysis 762 
We employed an established pipeline encoded in serial bash and Perl scripts used 763 
previously for the genomic analysis of P. aeruginosa PA14 (Jansen et al. 2015). Briefly, 764 
reads with unreliable quality were removed using Skewer (Jiang et al. 2014). Samples 765 
were then mapped to the published P. aeruginosa_UCBPP_PA14_uid57977 reference 766 
genome available at 767 
(ftp://ftp.ncbi.nih.gov/genomes/Bacteria/Pseudomonas_aeruginosa_UCBPP_PA14_u768 
id57977). Mapping was performed using bwa and samtools (Li et al. 2009; Li and 769 
Durbin 2010) and then visually inspected for low-quality areas using IGV (Integrated 770 
genome viewer, Broad Institute; www.broadinstitute.org/software/igv/).  771 
 772 
Duplicated regions were removed for single nucleotide polymorphisms and structural 773 
variant calling (SNPs and SV) using MarkDuplicates in Picardtools 774 
(http://picard.source-forge.net). To call SNPs and small indels above a threshold 775 
frequency of 0.1 and base quality above 20 we employed both frequentist and heuristic 776 
methods using respectively SNVer and VarScan (Wei et al. 2011; Koboldt et al. 2012). 777 
 29 
To identify larger indels and other SV, we used Pindel and CNVnator (Ye et al. 2009; 778 
Abyzov et al. 2011). The resulting output files were filtered for duplicates, ancestral 779 
variants, and variants found in the evolved controls. We used a combination of sources 780 
to identify and annotate the variants using snpEff (Cingolani et al. 2012), DAVID, the 781 
Pseudomonas database (available online at: http://pseudomonas.com) and information 782 
from published work. Further count statistics, analysis and visualizations were done in 783 
the R platform (R Core Team). 784 
 785 
Mutational diversity was calculated as in (Chevereau et al. 2015). Briefly, we calculated 786 
the entropy , where pj is the probability that a 787 
given locus j is mutated in a random population. H then measures the diversity of 788 
mutated loci in the populations adapted to a given drug. Standard error was obtained 789 
from jackknife resampling in the R platform.  790 
 791 
In order to link the observed collateral effects to the underlying genetic changes we 792 
performed a hierarchical clustering analysis. For this, we focused on four treatments, 793 
which repeatedly produced contrasting patterns of collateral effects. These included 794 
populations adapted to either GEN or STR (the two aminoglycosides), which produced 795 
variation in their collateral profiles towards PIT and CAR. We also considered the 796 
reverse two cases, for which replicated populations that had adapted to PIT and CAR 797 
showed contrasting patterns of collateral effects towards GEN and STR. For these four 798 
cases, we first obtained the Euclidean similarity of the sensitivities of evolved 799 
populations against the considered drugs. Then we used hierarchical clustering based 800 
on Ward’s minimum variance method, including the Ward’s criterion, which aims at 801 
finding compact, spherical clusters, and combined it with bootstrapping to asses cluster 802 
stability (Murtagh and Legendre 2014). The same process was then used to infer 803 
clusters based on the genomic profiles of the same populations, including only genes 804 
with mutations within their coding regions. For each antibiotic we then built 805 
dendograms for the clustering results and assessed to what extent given genomic 806 
clusters coincided with clusters having collateral resistance or sensitivity phenotypes.  807 
 808 
The obtained genome sequences are available from NCBI SRA database under the 809 
BioProject number: PRJNA355367. 810 
H =- [pj (log2 pj + (1- pj log2(1- pj )]å
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 811 
P. aeruginosa PA14 genome editing 812 
Deletion of nalC and single nucleotide mutations in pmrB and mexZ were performed in 813 
P. aeruginosa PA14 based on a two-step recombination method previously described 814 
(Trebosc et al. 2016). DNA fragments corresponding to 700-bp up- and downstream of 815 
the nalC region to be deleted (position 1,391,565-1,390,977 on PA14 genome, 816 
GenBank CP000438.1) were amplified by PCR using primers oVT464/oVT465 and 817 
oVT466/oVT467, respectively. The resulting DNA fragments were introduced into 818 
pVT77 previously digested with EcoRI/XbaI using NEBuilder HiFi DNA assembly 819 
(New England Biolabs). For the allelic replacement of wildtype pmrB and mexZ, 1.4-820 
kb DNA fragments were amplified by PCR using primers oVT468/469, oVT470/471 821 
and oVT472/473 on the evolved populations GEN-3, GEN-10, and STR-2, which 822 
respectively contained the PmrB_V136E, PmrB_P254L and MexZ_Q95stop 823 
mutations. The resulting DNA fragments were cloned into pVT77, digested with 824 
EcoRI/XbaI, using NEBuilder HiFi DNA assembly. 825 
 826 
The obtained plasmids were transformed into E. coli conjugative strains MFDpir or 827 
S17-1 and transferred into P. aeruginosa PA14 as described previously (Trebosc et al. 828 
2016). After conjugation, genomic plasmid integration was tested on LB agar plates 829 
containing 100 µg/ml sodium tellurite – when E. coli S17-1 was used additional 30 830 
µg/ml Chloramphenicol were added to selection plates to eradicate the E. coli cells. 831 
Plasmid integration into the PA14 genome was confirmed by PCR with primers oVT8 832 
and oVT474, oVT476, oVT478 and oVT480 for nalC deletion, PmrB V136E, PmrB 833 
P254L and MexZ Q95stop mutations, respectively. PA14 clones were transferred to 834 
LB agar plates containing 1 mM isopropyl-β-D-1-thiogalactopyranoside and 200 µg/ml 835 
3’-azido-3’-deoxythymidine to select for plasmid removal from the genome. Clones 836 
were screened by PCR using primers oVT474/oVT475, oVT476/oVT477, 837 
oVT478/oVT479 and oVT480/oVT481 for nalC deletion, PmrB V136E, PmrB P254L 838 
and MexZ Q95stop mutations, respectively. The genomic deletion and mutations were 839 
finally confirmed by DNA sequencing (Microsynth AG, Balgach, Switzerland). 840 
 841 
Table 2. Oligonucleotides used 842 
Oligo name Sequence (5’-3’) 
oVT8 GTTTTCCCAGTCACGACGC 
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oVT464 AGAATTGAGGCCTCTCGAGGAATTCTTAGAGGTCCCAGGCATTG 
oVT465 TGAGGAACAGGGTTTGCTGAGAGCGTTTC 
oVT466 TCAGCAAACCCTGTTCCTCAAGGCCCTC 
oVT467 CCGCAAGCTTCCTGCAGGCTCTAGACTGATGGAAACCTTTGCC 
oVT468 AGAATTGAGGCCTCTCGAGGAATTCTCGATCTCGACGAACTGC 
oVT469 CCGCAAGCTTCCTGCAGGCTCTAGACAACGACAGCTCGATGTC 
oVT470 AGAATTGAGGCCTCTCGAGGAATTCCTCTCGCTGAAGCAGGTG 
oVT471 CCGCAAGCTTCCTGCAGGCTCTAGAATCATCTTCGGCGTCAGTC 
oVT472 AGAATTGAGGCCTCTCGAGGAATTCTCCTGGCCTTCCTCGTAC 
oVT473 CCGCAAGCTTCCTGCAGGCTCTAGAAGGTAGGCGGAGAAAACG 
oVT474 TCTGCGCGGATTCTGATAGC 
oVT475 TCCCTGGAAATGCAGTGAGC 
oVT476 GACGACTACCTGACCAAGCC 
oVT477 CCTTCAGCCACAGGTCGATG 
oVT478 CGAGGTCCATGTCCATCACC 
oVT479 TCGTTCTCGTTGTAGTGGCG 
oVT480 CCTTGATCAGGTCGGCGTAG 
oVT481 AAGCTACCGTGACAGAACCC 
 843 
 844 
Acknowledgements 845 
 846 
We thank Anette Friedrichs, Lutz Becks, and the Schulenburg group for valuable advice 847 
and Melanie Vollstedt for technical support during genome sequencing. We are grateful 848 
for financial support from the German Science Foundation (DFG grant SCHU 1415/12-849 
1) and the International Max-Planck Research School for Evolutionary Biology at the 850 
University of Kiel. We acknowledge infrastructural support by the DFG excellence 851 
cluster Inflammation at Interfaces. 852 
  853 
 32 
References 854 
Abyzov A, Urban AE, Snyder M, Gerstein M. 2011. CNVnator: An approach to 855 
discover, genotype and characterize typical and atypical CNVs from family 856 
and population genome sequencing. Genome Res.:gr.114876.110. 857 
Aires JR, Köhler T, Nikaido H, Plésiat P. 1999. Involvement of an Active Efflux 858 
System in the Natural Resistance of Pseudomonas aeruginosa to 859 
Aminoglycosides. Antimicrob. Agents Chemother. 43:2624–2628. 860 
Amin NE, Giske CG, Jalal S, Keijser B, Kronvall G, Wretlind B. 2005. Carbapenem 861 
resistance mechanisms in Pseudomonas aeruginosa: alterations of porin 862 
OprD and efflux proteins do not fully explain resistance patterns observed 863 
in clinical isolates. APMIS 113:187–196. 864 
Andersson DI, Hughes D. 2010. Antibiotic resistance and its cost: is it possible to 865 
reverse resistance? Nat. Rev. Microbiol. 8:260–271. 866 
Arruda EAG MD, Marinho IS MD, Boulos M MD, Sinto SI BSc, F. HHC BSc, Mendes 867 
CM MD, Oplustil CP BSc, Sader H MD, Levy CE MD, Levin AS MD. 1999. 868 
Nosocomial Infections Caused by Multiresistant Pseudomonas 869 
aeruginosa •. Infect. Control Hosp. Epidemiol. 20:620–623. 870 
Balasubramanian D, Schneper L, Kumari H, Mathee K. 2013. A dynamic and 871 
intricate regulatory network determines Pseudomonas aeruginosa 872 
virulence. Nucleic Acids Res. 41:1–20. 873 
Barrick JE, Yu DS, Yoon SH, Jeong H, Oh TK, Schneider D, Lenski RE, Kim JF. 2009. 874 
Genome evolution and adaptation in a long-term experiment with 875 
Escherichia coli. Nature 461:1243–1247. 876 
Baym M, Lieberman TD, Kelsic ED, Chait R, Gross R, Yelin I, Kishony R. 2016. 877 
Spatiotemporal microbial evolution on antibiotic landscapes. Science 878 
353:1147–1151. 879 
Baym M, Stone LK, Kishony R. 2016. Multidrug evolutionary strategies to reverse 880 
antibiotic resistance. Science 351:aad3292. 881 
Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, Hall 882 
KP, Evers DJ, Barnes CL, Bignell HR, et al. 2008. Accurate whole human 883 
genome sequencing using reversible terminator chemistry. Nature 884 
456:53–59. 885 
Breidenstein EBM, de la Fuente-Núñez C, Hancock REW. 2011. Pseudomonas 886 
aeruginosa: all roads lead to resistance. Trends Microbiol. 19:419–426. 887 
Burrows LL. 2012. Pseudomonas aeruginosa Twitching Motility: Type IV Pili in 888 
Action. Annu. Rev. Microbiol. 66:493–520. 889 
Cabot G, Zamorano L, Moyà B, Juan C, Navas A, Blázquez J, Oliver A. 2016. 890 
Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and 891 
 33 
Fitness under Low and High Mutation Rates. Antimicrob. Agents 892 
Chemother. 60:1767–1778. 893 
Cao L, Srikumar R, Poole K. 2004. MexAB-OprM hyperexpression in NalC-type 894 
multidrug-resistant Pseudomonas aeruginosa: identification and 895 
characterization of the nalC gene encoding a repressor of PA3720-896 
PA3719. Mol. Microbiol. 53:1423–1436. 897 
Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. 1999. Emergence of Antibiotic-898 
Resistant Pseudomonas aeruginosa: Comparison of Risks Associated with 899 
Different Antipseudomonal Agents. Antimicrob. Agents Chemother. 900 
43:1379–1382. 901 
Chait R, Craney A, Kishony R. 2007. Antibiotic interactions that select against 902 
resistance. Nature 446:668–671. 903 
Chevereau G, Dravecká M, Batur T, Guvenek A, Ayhan DH, Toprak E, Bollenbach 904 
T. 2015. Quantifying the Determinants of Evolutionary Dynamics Leading 905 
to Drug Resistance. PLoS Biol 13:e1002299. 906 
Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L, Land SJ, Lu X, Ruden 907 
DM. 2012. A program for annotating and predicting the effects of single 908 
nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila 909 
melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6:80–92. 910 
Ciofu O, Mandsberg LF, Bjarnsholt T, Wassermann T, Høiby N. 2010. Genetic 911 
adaptation of Pseudomonas aeruginosa during chronic lung infection of 912 
patients with cystic fibrosis: strong and weak mutators with 913 
heterogeneous genetic backgrounds emerge in mucA and/or lasR 914 
mutants. Microbiology 156:1108–1119. 915 
Daigle DM, Cao L, Fraud S, Wilke MS, Pacey A, Klinoski R, Strynadka NC, Dean CR, 916 
Poole K. 2007. Protein Modulator of Multidrug Efflux Gene Expression in 917 
Pseudomonas aeruginosa. J. Bacteriol. 189:5441–5451. 918 
Davies J, Davies D. 2010. Origins and Evolution of Antibiotic Resistance. 919 
Microbiol. Mol. Biol. Rev. 74:417–433. 920 
Doyle TB, Hawkins AC, McCarter LL. 2004. The Complex Flagellar Torque 921 
Generator of Pseudomonas aeruginosa. J. Bacteriol. 186:6341–6350. 922 
Drenkard E, Ausubel FM. 2002. Pseudomonas biofilm formation and antibiotic 923 
resistance are linked to phenotypic variation. Nature 416:740–743. 924 
Evgrafov MR de, Gumpert H, Munck C, Thomsen TT, Sommer MOA. 2015. 925 
Collateral Resistance and Sensitivity Modulate Evolution of High-Level 926 
Resistance to Drug Combination Treatment in Staphylococcus aureus. 927 
Mol. Biol. Evol. 32:1175–1185. 928 
 34 
Folkesson A, Jelsbak L, Yang L, Johansen HK, Ciofu O, Høiby N, Molin S. 2012. 929 
Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an 930 
evolutionary perspective. Nat. Rev. Microbiol. 10:841–851. 931 
Fuentes-Hernandez A, Plucain J, Gori F, Pena-Miller R, Reding C, Jansen G, 932 
Schulenburg H, Gudelj I, Beardmore R. 2015. Using a Sequential Regimen 933 
to Eliminate Bacteria at Sublethal Antibiotic Dosages. PLoS Biol 934 
13:e1002104. 935 
Furuya EY, Lowy FD. 2006. Antimicrobial-resistant bacteria in the community 936 
setting. Nat. Rev. Microbiol. 4:36–45. 937 
Gotoh N, Tsujimoto H, Tsuda M, Okamoto K, Nomura A, Wada T, Nakahashi M, 938 
Nishino T. 1998. Characterization of the MexC-MexD-OprJ Multidrug 939 
Efflux System in ΔmexA-mexB-oprM Mutants of Pseudomonas 940 
aeruginosa. Antimicrob. Agents Chemother. 42:1938–1943. 941 
Govan JR, Deretic V. 1996. Microbial pathogenesis in cystic fibrosis: mucoid 942 
Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol. Rev. 943 
60:539–574. 944 
Hancock REW, Speert DP. 2000. Antibiotic resistance in Pseudomonas 945 
aeruginosa: mechanisms and impact on treatment. Drug Resist. Updat. 946 
3:247–255. 947 
Hauser AR. 2009. The type III secretion system of Pseudomonas aeruginosa: 948 
infection by injection. Nat. Rev. Microbiol. 7:654–665. 949 
Hegreness M, Shoresh N, Damian D, Hartl D, Kishony R. 2008. Accelerated 950 
evolution of resistance in multidrug environments. Proc. Natl. Acad. Sci. 951 
105:13977–13981. 952 
Hoch JA. 2000. Two-component and phosphorelay signal transduction. Curr. 953 
Opin. Microbiol. 3:165–170. 954 
Imamovic L, Sommer MOA. 2013. Use of Collateral Sensitivity Networks to 955 
Design Drug Cycling Protocols That Avoid Resistance Development. Sci. 956 
Transl. Med. 5:204ra132-204ra132. 957 
Jansen G, Barbosa C, Schulenburg H. 2013. Experimental evolution as an efficient 958 
tool to dissect adaptive paths to antibiotic resistance. Drug Resist. Updat. 959 
16:96–107. 960 
Jansen G, Crummenerl LL, Gilbert F, Mohr T, Pfefferkorn R, Thänert R, Rosenstiel 961 
P, Schulenburg H. 2015. Evolutionary Transition from Pathogenicity to 962 
Commensalism: Global Regulator Mutations Mediate Fitness Gains 963 
through Virulence Attenuation. Mol. Biol. Evol. 32:2883–2896. 964 
Jeannot K, Elsen S, Köhler T, Attree I, van Delden C, Plésiat P. 2008. Resistance 965 
and Virulence of Pseudomonas aeruginosa Clinical Strains Overproducing 966 
 35 
the MexCD-OprJ Efflux Pump. Antimicrob. Agents Chemother. 52:2455–967 
2462. 968 
Jiang H, Lei R, Ding S-W, Zhu S. 2014. Skewer: a fast and accurate adapter 969 
trimmer for next-generation sequencing paired-end reads. BMC 970 
Bioinformatics 15:182. 971 
Jimenez PN, Koch G, Thompson JA, Xavier KB, Cool RH, Quax WJ. 2012. The 972 
Multiple Signaling Systems Regulating Virulence in Pseudomonas 973 
aeruginosa. Microbiol. Mol. Biol. Rev. 76:46–65. 974 
Kang C-I, Kim S-H, Kim H-B, Park S-W, Choe Y-J, Oh M, Kim E-C, Choe K-W. 2003. 975 
Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and 976 
Influence of Delayed Receipt of Effective Antimicrobial Therapy on 977 
Clinical Outcome. Clin. Infect. Dis. 37:745–751. 978 
Kim S, Lieberman TD, Kishony R. 2014. Alternating antibiotic treatments 979 
constrain evolutionary paths to multidrug resistance. Proc. Natl. Acad. Sci. 980 
111:14494–14499. 981 
Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis 982 
ER, Ding L, Wilson RK. 2012. VarScan 2: Somatic mutation and copy 983 
number alteration discovery in cancer by exome sequencing. Genome Res. 984 
[Internet]. Available from: 985 
http://genome.cshlp.org/content/early/2012/02/02/gr.129684.111 986 
Korotkov KV, Sandkvist M, Hol WGJ. 2012. The type II secretion system: 987 
biogenesis, molecular architecture and mechanism. Nat. Rev. Microbiol. 988 
10:336–351. 989 
Kugelberg E, Löfmark S, Wretlind B, Andersson DI. 2005. Reduction of the fitness 990 
burden of quinolone resistance in Pseudomonas aeruginosa. J. 991 
Antimicrob. Chemother. 55:22–30. 992 
Kussell E. 2013. Evolution in Microbes. Annu. Rev. Biophys. 42:493–514. 993 
Larson E. 2007. Community Factors in the Development of Antibiotic Resistance. 994 
Annu. Rev. Public Health 28:435–447. 995 
Lázár V, Nagy I, Spohn R, Csörgő B, Györkei Á, Nyerges Á, Horváth B, Vörös A, 996 
Busa-Fekete R, Hrtyan M, et al. 2014. Genome-wide analysis captures the 997 
determinants of the antibiotic cross-resistance interaction network. Nat. 998 
Commun. 5:4352. 999 
Lázár V, Singh GP, Spohn R, Nagy I, Horváth B, Hrtyan M, Busa‐Fekete R, Bogos B, 1000 
Méhi O, Csörgő B, et al. 2013. Bacterial evolution of antibiotic 1001 
hypersensitivity. Mol. Syst. Biol. [Internet] 9. Available from: 1002 
http://msb.embopress.org/content/9/1/700 1003 
 36 
Lenski RE, Rose MR, Simpson SC, Tadler SC. 1991. Long-Term Experimental 1004 
Evolution in Escherichia coli. I. Adaptation and Divergence During 2,000 1005 
Generations. Am. Nat. 138:1315–1341. 1006 
Levin-Reisman I, Ronin I, Gefen O, Braniss I, Shoresh N, Balaban NQ. 2017. 1007 
Antibiotic tolerance facilitates the evolution of resistance. 1008 
Science:eaaj2191. 1009 
Li H, Durbin R. 2010. Fast and accurate long-read alignment with Burrows–1010 
Wheeler transform. Bioinformatics 26:589–595. 1011 
Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, 1012 
Durbin R, Subgroup 1000 Genome Project Data Processing. 2009. The 1013 
Sequence Alignment/Map format and SAMtools. Bioinformatics 25:2078–1014 
2079. 1015 
Li X-Z, Zhang L, Poole K. 2000. Interplay between the MexA-MexB-OprM 1016 
multidrug efflux system and the outer membrane barrier in the multiple 1017 
antibiotic resistance of Pseudomonas aeruginosa. J. Antimicrob. 1018 
Chemother. 45:433–436. 1019 
Livermore DM. 2002. Multiple Mechanisms of Antimicrobial Resistance in 1020 
Pseudomonas aeruginosa: Our Worst Nightmare? Clin. Infect. Dis. 1021 
34:634–640. 1022 
Loper JE, Hassan KA, Mavrodi DV, Ii EWD, Lim CK, Shaffer BT, Elbourne LDH, 1023 
Stockwell VO, Hartney SL, Breakwell K, et al. 2012. Comparative Genomics 1024 
of Plant-Associated Pseudomonas spp.: Insights into Diversity and 1025 
Inheritance of Traits Involved in Multitrophic Interactions. PLOS Genet 1026 
8:e1002784. 1027 
Ma L, Conover M, Lu H, Parsek MR, Bayles K, Wozniak DJ. 2009. Assembly and 1028 
Development of the Pseudomonas aeruginosa Biofilm Matrix. PLoS 1029 
Pathog 5:e1000354. 1030 
Macfarlane ELA, Kwasnicka A, Hancock REW. 2000. Role of Pseudomonas 1031 
aeruginosa PhoP-PhoQ in resistance to antimicrobial cationic peptides 1032 
and aminoglycosides. Microbiology 146:2543–2554. 1033 
Maseda H, Yoneyama H, Nakae T. 2000. Assignment of the Substrate-Selective 1034 
Subunits of the MexEF-OprN Multidrug Efflux Pump of Pseudomonas 1035 
aeruginosa. Antimicrob. Agents Chemother. 44:658–664. 1036 
Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. 2000. Substrate 1037 
Specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM Efflux 1038 
Pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1039 
44:3322–3327. 1040 
McPhee JB, Lewenza S, Hancock REW. 2003. Cationic antimicrobial peptides 1041 
activate a two-component regulatory system, PmrA-PmrB, that regulates 1042 
 37 
resistance to polymyxin B and cationic antimicrobial peptides in 1043 
Pseudomonas aeruginosa. Mol. Microbiol. 50:205–217. 1044 
Melnyk AH, Wong A, Kassen R. 2015. The fitness costs of antibiotic resistance 1045 
mutations. Evol. Appl. 8:273–283. 1046 
Michel J-B, Yeh PJ, Chait R, Moellering RC, Kishony R. 2008. Drug interactions 1047 
modulate the potential for evolution of resistance. Proc. Natl. Acad. Sci. 1048 
105:14918–14923. 1049 
Miller C, Thomsen LE, Gaggero C, Mosseri R, Ingmer H, Cohen SN. 2004. SOS 1050 
Response Induction by ß-Lactams and Bacterial Defense Against 1051 
Antibiotic Lethality. Science 305:1629–1631. 1052 
Montanari S, Oliver A, Salerno P, Mena A, Bertoni G, Tümmler B, Cariani L, Conese 1053 
M, Döring G, Bragonzi A. 2007. Biological cost of hypermutation in 1054 
Pseudomonas aeruginosa strains from patients with cystic fibrosis. 1055 
Microbiology 153:1445–1454. 1056 
Munck C, Gumpert HK, Wallin AIN, Wang HH, Sommer MOA. 2014. Prediction of 1057 
resistance development against drug combinations by collateral 1058 
responses to component drugs. Sci. Transl. Med. 6:262ra156-262ra156. 1059 
Murtagh F, Legendre P. 2014. Ward’s Hierarchical Agglomerative Clustering 1060 
Method: Which Algorithms Implement Ward’s Criterion? J. Classif. 1061 
31:274–295. 1062 
Nikel PI, Martínez-García E, de Lorenzo V. 2014. Biotechnological domestication 1063 
of pseudomonads using synthetic biology. Nat. Rev. Microbiol. 12:368–1064 
379. 1065 
Oliver A, Baquero F, Blázquez J. 2002. The mismatch repair system (mutS, mutL 1066 
and uvrD genes) in Pseudomonas aeruginosa: molecular characterization 1067 
of naturally occurring mutants. Mol. Microbiol. 43:1641–1650. 1068 
Overhage J, Bains M, Brazas MD, Hancock REW. 2008. Swarming of Pseudomonas 1069 
aeruginosa Is a Complex Adaptation Leading to Increased Production of 1070 
Virulence Factors and Antibiotic Resistance. J. Bacteriol. 190:2671–2679. 1071 
Oz T, Guvenek A, Yildiz S, Karaboga E, Tamer YT, Mumcuyan N, Ozan VB, Senturk 1072 
GH, Cokol M, Yeh P, et al. 2014. Strength of Selection Pressure Is an 1073 
Important Parameter Contributing to the Complexity of Antibiotic 1074 
Resistance Evolution. Mol. Biol. Evol. 31:2387–2401. 1075 
Pál C, Papp B, Lázár V. 2015. Collateral sensitivity of antibiotic-resistant 1076 
microbes. Trends Microbiol. 23:401–407. 1077 
Pena-Miller R, Laehnemann D, Jansen G, Fuentes-Hernandez A, Rosenstiel P, 1078 
Schulenburg H, Beardmore R. 2013. When the Most Potent Combination 1079 
of Antibiotics Selects for the Greatest Bacterial Load: The Smile-Frown 1080 
Transition. PLoS Biol 11:e1001540. 1081 
 38 
Piddock LJV. 2006. Multidrug-resistance efflux pumps ? not just for resistance. 1082 
Nat. Rev. Microbiol. 4:629–636. 1083 
Poole K. 2001. Multidrug efflux pumps and antimicrobial resistance in 1084 
Pseudomonas aeruginosa and related organisms. J Mol Microb. Biotechnol 1085 
3:255–264. 1086 
R Core Team. R: A Language and Environment for Statistical Computing. Vienna, 1087 
Austria: R Foundation for Statistical Computing Available from: 1088 
https://www.R-project.org/ 1089 
Ramos JL, Martínez-Bueno M, Molina-Henares AJ, Terán W, Watanabe K, Zhang X, 1090 
Gallegos MT, Brennan R, Tobes R. 2005. The TetR Family of 1091 
Transcriptional Repressors. Microbiol. Mol. Biol. Rev. 69:326–356. 1092 
Robinson VL, Buckler DR, Stock AM. 2000. A tale of two components: a novel 1093 
kinase and a regulatory switch. Nat. Struct. Mol. Biol. 7:626–633. 1094 
Rodrigue A, Quentin Y, Lazdunski A, Méjean V, Foglino M. 2000. Cell signalling by 1095 
oligosaccharides. Two-component systems in Pseudomonas aeruginosa: 1096 
why so many? Trends Microbiol. 8:498–504. 1097 
Rodríguez-Rojas A, Oliver A, Blázquez J. 2012. Intrinsic and Environmental 1098 
Mutagenesis Drive Diversification and Persistence of Pseudomonas 1099 
aeruginosa in Chronic Lung Infections. J. Infect. Dis. 205:121–127. 1100 
Roemhild R, Barbosa C, Beardmore RE, Jansen G, Schulenburg H. 2015. Temporal 1101 
variation in antibiotic environments slows down resistance evolution in 1102 
pathogenic Pseudomonas aeruginosa. Evol. Appl.:n/a-n/a. 1103 
Szybalski W, Bryson V. 1952. GENETIC STUDIES ON MICROBIAL CROSS 1104 
RESISTANCE TO TOXIC AGENTS I. ,. J. Bacteriol. 64:489–499. 1105 
Tenaillon O, Barrick JE, Ribeck N, Deatherage DE, Blanchard JL, Dasgupta A, Wu 1106 
GC, Wielgoss S, Cruveiller S, Médigue C, et al. 2016. Tempo and mode of 1107 
genome evolution in a 50,000-generation experiment. Nature 536:165–1108 
170. 1109 
Toprak E, Veres A, Michel J-B, Chait R, Hartl DL, Kishony R. 2012. Evolutionary 1110 
paths to antibiotic resistance under dynamically sustained drug selection. 1111 
Nat. Genet. 44:101–105. 1112 
Trebosc V, Gartenmann S, Royet K, Manfredi P, Tötzl M, Schellhorn B, Pieren M, 1113 
Tigges M, Lociuro S, Sennhenn PC, et al. 2016. A Novel Genome-Editing 1114 
Platform for Drug-Resistant Acinetobacter baumannii Reveals an AdeR-1115 
Unrelated Tigecycline Resistance Mechanism. Antimicrob. Agents 1116 
Chemother. 60:7263–7271. 1117 
Tsutsumi Y, Tomita H, Tanimoto K. 2013. Identification of Novel Genes 1118 
Responsible for Overexpression of ampC in Pseudomonas aeruginosa 1119 
PAO1. Antimicrob. Agents Chemother. 57:5987–5993. 1120 
 39 
Wei Z, Wang W, Hu P, Lyon GJ, Hakonarson H. 2011. SNVer: a statistical tool for 1121 
variant calling in analysis of pooled or individual next-generation 1122 
sequencing data. Nucleic Acids Res. 39:e132–e132. 1123 
Westbrock-Wadman S, Sherman DR, Hickey MJ, Coulter SN, Zhu YQ, Warrener P, 1124 
Nguyen LY, Shawar RM, Folger KR, Stover CK. 1999. Characterization of a 1125 
Pseudomonas aeruginosa Efflux Pump Contributing to Aminoglycoside 1126 
Impermeability. Antimicrob. Agents Chemother. 43:2975–2983. 1127 
Ye K, Schulz MH, Long Q, Apweiler R, Ning Z. 2009. Pindel: a pattern growth 1128 
approach to detect break points of large deletions and medium sized 1129 
insertions from paired-end short reads. Bioinformatics 25:2865–2871. 1130 
 1131 
